CTSA: A Drug Target / Disease Biomarker (G5476)

Target Name: CTSA

NCBI ID: G5476

CTSA

CTSA: A Drug Target / Disease Biomarker

CTSA, short for curcumin triacetate, is a drug target and a biomarker that has been gaining significant attention in recent years due to its potential in treating various diseases, including cancer. Its unique structure, which consists of a curcumin core and three acetyl groups attached to the carbon atom, makes it an interesting compound that can interact with a variety of molecules in the body.

The curcumin core of CTSA is a well-known compound that is found in turmeric, a commonly used spice in many cuisines. This compound has been shown to have various health benefits, including anti-inflammatory and antioxidant effects. The three acetyl groups attached to the carbon atom of CTSA allow it to interact with other molecules in the body, which is thought to be the key to its potential therapeutic uses.

One of the most promising aspects of CTSA is its ability to target cancer cells. Cancer cells have a unique way of growing and spreading, and CTSA has been shown to interfere with this process. CTSA has been shown to inhibit the growth of cancer cells in various studies, including those of breast, lung, and ovarian cancer. This makes CTSA a potential drug target for cancer treatment.

In addition to its potential as a cancer drug target, CTSA has also been shown to be a valuable biomarker for several diseases. For example, CTSA has been shown to be elevated in the blood of patients with various diseases, including cancer. This suggests that it may be a useful diagnostic tool for diseases that affect the body's immune system.

Another potential use of CTSA is its ability to modulate cellular signaling pathways. CTSA has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in cell growth, survival, and angiogenesis, and is thought to be involved in the development and progression of many diseases. By modulating this pathway, CTSA may have potential therapeutic applications for a variety of diseases.

CTSA has also been shown to have potential applications in neuroscience research. The curcumin core of CTSA has been shown to interact with various neurotransmitters, including dopamine and GABA. This suggests that CTSA may have potential therapeutic applications for disorders of the nervous system, such as Parkinson's disease and Alzheimer's disease.

In conclusion, CTSA is a drug target and a biomarker that has gained significant attention in recent years due to its potential in treating various diseases. Its unique structure, which consists of a curcumin core and three acetyl groups attached to the carbon atom, makes it an interesting compound that can interact with a variety of molecules in the body. As more research is conducted on CTSA, it is likely to become a valuable tool for the treatment of a variety of diseases.

Protein Name: Cathepsin A

Functions: Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins

The "CTSA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTSA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets